Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GKOSNYSE:STVNNASDAQ:TMDXNYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGKOSGlaukos$100.61+3.1%$92.76$77.10▼$163.71$5.75B0.8725,638 shs412,483 shsSTVNStevanato Group€23.65+0.7%€22.44€16.56▼€25.75$7.16B0.53335,617 shs100,436 shsTMDXTransMedics Group$142.10-0.5%$108.75$55.00▼$177.37$4.79B2.11.36 million shs324,504 shsWRBYWarby Parker$22.02-0.2%$17.91$12.46▼$28.68$2.31B2.11.95 million shs867,099 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGKOSGlaukos0.00%+5.00%+2.35%-5.27%-13.24%STVNStevanato Group0.00%-1.68%-2.38%+12.99%+31.68%TMDXTransMedics Group0.00%+2.75%+17.52%+111.08%+0.61%WRBYWarby Parker0.00%+2.01%+24.46%+8.30%+35.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGKOSGlaukos4.4304 of 5 stars4.42.00.04.41.72.50.6STVNStevanato Group1.6094 of 5 stars0.04.01.70.01.30.01.9TMDXTransMedics Group1.2949 of 5 stars1.42.00.00.01.42.51.9WRBYWarby Parker1.8685 of 5 stars2.32.00.00.02.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGKOSGlaukos 2.75Moderate Buy$134.6733.85% UpsideSTVNStevanato Group 2.86Moderate BuyN/AN/ATMDXTransMedics Group 2.80Moderate Buy$125.11-11.96% DownsideWRBYWarby Parker 2.61Moderate Buy$22.883.88% UpsideCurrent Analyst Ratings BreakdownLatest WRBY, STVN, GKOS, and TMDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.006/3/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/29/2025WRBYWarby ParkerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.00 ➝ $25.005/22/2025WRBYWarby ParkerRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$18.00 ➝ $21.005/21/2025WRBYWarby ParkerCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$17.00 ➝ $22.005/21/2025WRBYWarby ParkerStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$18.00 ➝ $21.005/21/2025WRBYWarby ParkerTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $24.005/13/2025WRBYWarby ParkerUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$23.00 ➝ $20.005/9/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGKOSGlaukos$404.52M14.21N/AN/A$9.46 per share10.64STVNStevanato Group$1.12B6.37€0.99 per share23.97€4.15 per share5.70TMDXTransMedics Group$488.23M9.84$0.27 per share530.08$4.20 per share33.83WRBYWarby Parker$795.09M2.89N/AN/A$3.08 per share7.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGKOSGlaukos-$134.66M-$2.37N/AN/AN/A-39.04%-16.53%-10.61%7/30/2025 (Estimated)STVNStevanato Group$157.62M€0.5150.3240.787.1810.47%9.86%5.79%N/ATMDXTransMedics Group-$25.03M$1.36150.5099.37N/A8.14%18.74%4.39%7/30/2025 (Estimated)WRBYWarby Parker-$63.20M-$0.12N/A220.20N/A-4.39%-8.26%-4.37%8/6/2025 (Estimated)Latest WRBY, STVN, GKOS, and TMDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025TMDXTransMedics Group$0.29$0.70+$0.41$0.70$123.39 million$143.54 million4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGKOSGlaukosN/AN/AN/AN/AN/ASTVNStevanato Group€0.060.25%N/A11.76%1 YearsTMDXTransMedics GroupN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ALatest WRBY, STVN, GKOS, and TMDX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025STVNStevanato Groupannual€0.060.3%6/5/20256/5/20257/17/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGKOSGlaukos0.195.544.71STVNStevanato Group0.221.811.21TMDXTransMedics Group2.428.207.33WRBYWarby ParkerN/A2.472.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGKOSGlaukos99.04%STVNStevanato GroupN/ATMDXTransMedics Group99.67%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipGKOSGlaukos5.80%STVNStevanato Group0.70%TMDXTransMedics Group7.00%WRBYWarby Parker18.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGKOSGlaukos78057.14 million51.61 millionOptionableSTVNStevanato Group4,650302.84 million300.72 millionOptionableTMDXTransMedics Group21033.82 million31.21 millionOptionableWRBYWarby Parker3,030104.50 million74.67 millionOptionableWRBY, STVN, GKOS, and TMDX HeadlinesRecent News About These CompaniesVaughan Nelson Investment Management L.P. Trims Stake in Warby Parker Inc. (NYSE:WRBY)June 15 at 5:55 AM | marketbeat.comWarby Parker Inc. (NYSE:WRBY) Receives $22.88 Average Price Target from BrokeragesJune 14 at 2:05 AM | americanbankingnews.comTech Giants Partner With Retailers As Smart Glasses Battle Heats UpJune 12, 2025 | forbes.comWarby Parker eyes space at trendy Raleigh shopping centerJune 11, 2025 | bizjournals.comWarby Parker Inc. (NYSE:WRBY) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 11, 2025 | marketbeat.comWRBY Q1 Earnings Call: Management Details Tariff Mitigation, Store Expansion, and Pricing ActionsJune 10, 2025 | msn.comNBC Securities Inc. Buys 11,574 Shares of Warby Parker Inc. (NYSE:WRBY)June 9, 2025 | marketbeat.comAmeriprise Financial Inc. Acquires New Shares in Warby Parker Inc. (NYSE:WRBY)June 6, 2025 | marketbeat.comWarby Parker Co-CEO: Google AI Glasses Coming After 2025June 4, 2025 | pymnts.comWarby Parker (NYSE:WRBY) Shares Down 3.3% - What's Next?June 4, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.29 Million Holdings in Warby Parker Inc. (NYSE:WRBY)June 3, 2025 | marketbeat.comWarby Parker Announces Participation in the Baird Global Consumer, Technology & Services ConferenceJune 2, 2025 | finance.yahoo.comJune 2, 2025 | gurufocus.comWarby Parker (NYSE:WRBY) Trading Up 3% - Still a Buy?May 31, 2025 | marketbeat.comInsider Selling: Warby Parker Inc. (NYSE:WRBY) Director Sells 33,073 Shares of StockMay 29, 2025 | marketbeat.comTwo Sigma Advisers LP Increases Stake in Warby Parker Inc. (NYSE:WRBY)May 29, 2025 | marketbeat.comGoogle Is Back to Smart Glasses: This Time It Might WorkMay 28, 2025 | techopedia.comYoungme E. Moon Sells 33,073 Shares of Warby Parker Inc. (NYSE:WRBY) StockMay 28, 2025 | insidertrades.comWarby Parker Inc. (NYSE:WRBY) Shares Acquired by Two Sigma Investments LPMay 28, 2025 | marketbeat.comLoop Capital Maintains Buy Rating on Warby Parker (WRBY) StockMay 27, 2025 | insidermonkey.comWoodline Partners LP Sells 85,914 Shares of Warby Parker Inc. (NYSE:WRBY)May 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBy Leo Miller | June 12, 2025View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayWRBY, STVN, GKOS, and TMDX Company DescriptionsGlaukos NYSE:GKOS$100.61 +3.01 (+3.08%) As of 12:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Stevanato Group NYSE:STVN€23.65 +0.17 (+0.72%) As of 12:24 PM EasternStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.TransMedics Group NASDAQ:TMDX$142.10 -0.78 (-0.55%) As of 12:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Warby Parker NYSE:WRBY$22.02 -0.04 (-0.18%) As of 12:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
